Moximed to Unveil Data from Pivotal Study of MISHA™ Knee System for First Time at Orthopaedic Summit (OSET) 2022

Two CME presentations and a lunch symposium will feature the world’s first implantable shock absorber (ISA) for knee osteoarthritis

Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that David R. Diduch, MD, the A.F. Voshell Professor of Sports Medicine, Department of Sports Medicine, University of Virginia, will present key data from the pivotal study of the MISHA™ Knee System at the 12^th Orthopaedic Summit (OSET). A presentation of the implantable shock absorber’s (ISA’s) design and clinical evolution will also be presented by Andreas H. Gomoll, MD, Professor of Orthopedic Surgery at the Hospital for Special Surgery in New York. The conference will take place September 21-24, 2022 in Boston.

The presentations will be part of a CME-accredited surgical congress and will be featured in a session on Knee Cartilage and Biologics. Specifically, the faculty were asked to consider treatment options for a 43-year-old with moderate, but chronically painful, knee OA who wishes to remain physically active.

Session: Knee Cartilage and Biologics

Presenter: Andreas H. Gomoll, MD, Hospital for Special Surgery (HSS) in New York

Location: Encore Boston Harbor; Monet 1, 2 & 3

Date and Time: Thursday, September 22, 2022; 10:56 AM - 11:01 AM ET

Session: Knee Cartilage and Biologics

Presenter: David R. Diduch, MD, University of Virginia

Location: Encore Boston Harbor; Monet 1, 2 & 3

Date and Time: Thursday, September 22, 2022; 11:21 AM - 11:26 AM ET

Moximed will also host a lunch symposium at 12:40 PM ET on Thursday, September 22 in the Monet Room, titled 1st Implantable Shock Absorber for Unloading the Knee: Case Conversations with Experienced Surgeons and Clinical Study Patients. The session will consist of a panel of clinical study patients and the following faculty, who will discuss the device function, treatment indications, and clinical study patient experiences: Anil S. Ranawat, MD, Hospital for Special Surgery (HSS) in New York; David R. Diduch, MD, University of Virginia Health; David C. Flanigan, MD, Ohio State University, Wexner Medical Center; Dennis C. Crawford, MD, PhD, Oregon Health & Safety University; and Andreas H. Gomoll, MD, Hospital for Special Surgery (HSS) in New York.

About Moximed

Moximed was founded in 2008 and is dedicated to helping people with mild to moderate osteoarthritis preserve their knee joints while living healthy, active lives. The company’s technology, the MISHA™ Knee System, is the first implantable shock absorber for the treatment of medial compartment knee osteoarthritis (OA). With experienced medtech leadership and financing exceeding $150 million, Moximed is poised to bring MISHA to market and elevate the standard of care and quality of life for millions of people hindered by arthritic knee pain and function loss. Moximed is based in Fremont, California.

About The MISHA™ Knee System

Reducing weight on painful osteoarthritic joints is known to reduce pain and improve function. The MISHA™ Knee System being developed is the first implantable shock absorber that reduces weight on the knee joint with every walking step, easing pain, preserving function, and possibly delaying joint replacement surgery. The implant is placed on the medial knee and moves with the natural joint, reducing about 30% of the peak force on the knee with every walking step.^[1]

¹ Morgan OJ, Hillstrom HJ, Ranawat A, Fragomen AT, Rozbruch SR, Hillstrom R. Effects of a Medial Knee Unloading Implant on Tibiofemoral Joint Mechanics During Walking. J Orthop Res. 2019;37(10):2149-2156. doi:10.1002/jor.24379.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005255/en/